The dopamine hypothesis of schizophrenia proposes that hyperactivity of dopaminergic transmission is associated with this illness, but direct observation of abnormalities of dopamine function in schizophrenia has remained elusive. We used a newly developed single photon emission computerized tomography method to measure amphetamineinduced dopamine release in the striatum of fifteen patients with schizophrenia and fifteen healthy controls. Amphetamine-induced dopamine release was estimated by the amphetamine-induced reduction in dopamine D2 receptor availability, measured as the binding potential of the specific D2 receptor radiotracer [1231] The dopamine hypothesis of schizophrenia, formulated over 30 years ago, proposes that hyperactivity of dopaminergic transmission is associated with this illness (1). This hypothesis is based on the observation that dopamine D2 receptor antagonists alleviate symptoms of the illness (mostly positive symptoms), while dopamine agonists can induce psychotic states characterized by some salient features of schizophrenia (2). These pharmacological effects suggest, but do not establish, a dysregulation of dopamine systems in schizophrenia. Despite decades of effort to validate this hypothesis, documentation of abnormalities of dopamine function in schizophrenia has remained elusive. Postmortem studies measuring dopamine and its metabolites in the brain of schizophrenic patients have yielded inconsistent results (for review, see ref.
computerized tomography method to measure amphetamineinduced dopamine release in the striatum of fifteen patients with schizophrenia and fifteen healthy controls. Amphetamine-induced dopamine release was estimated by the amphetamine-induced reduction in dopamine D2 receptor availability, measured as the binding potential of the specific D2 receptor radiotracer [1231] The dopamine hypothesis of schizophrenia, formulated over 30 years ago, proposes that hyperactivity of dopaminergic transmission is associated with this illness (1) . This hypothesis is based on the observation that dopamine D2 receptor antagonists alleviate symptoms of the illness (mostly positive symptoms), while dopamine agonists can induce psychotic states characterized by some salient features of schizophrenia (2) . These pharmacological effects suggest, but do not establish, a dysregulation of dopamine systems in schizophrenia. Despite decades of effort to validate this hypothesis, documentation of abnormalities of dopamine function in schizophrenia has remained elusive. Postmortem studies measuring dopamine and its metabolites in the brain of schizophrenic patients have yielded inconsistent results (for review, see ref. 3) . Increased density of striatal dopamine D2 and D2-like receptors has been reported in postmortem studies, but this observation is difficult to interpret, given that neuroleptic drugs upregulate these receptors (4, 5) . Positron emission tomography and single photon emission computerized tomography (SPECT) studies of striatal D2 and D2-like receptors density in neurolepticnaive schizophrenic patients have been inconclusive. While one group reported increased striatal D2-like receptors density in schizophrenia (6, 7) , other groups reported negative results (8) (9) (10) (11) (12) . The lack of clear evidence for increased dopaminergic indices in schizophrenia might indicate that dopaminergic transmission is enhanced only relative to other systems, such as serotonergic or glutamatergic systems (13, 14) . On the other hand, the absence of data supporting the dopamine hypothesis of schizophrenia might be due to the difficulty of obtaining direct measurement of dopamine transmission in the living human brain.
Over the past few years, several groups have provided evidence that competition between neurotransmitters and radioligands for neuroreceptor binding allows measuring changes in synaptic neurotransmitter levels with in vivo binding techniques. In rodents, decreased uptake of D2 radioligands has been measured following amphetamine and other dopamine enhancing drugs, whereas the opposite effect (i.e., increased tracer accumulation) has been induced by drugs that decrease dopamine concentration (15) (16) (17) . In baboons, decreased specific uptake of positron emission tomography or SPECT D2 radiotracers has been reported following amphetamine challenge (18) (19) (20) . In humans, decreased accumulation of the D2 antagonist [11C]raclopride has been observed following challenges with amphetamine (21) or methylphenidate (22) .
We recently developed and validated a protocol to measure amphetamine-induced dopamine release with SPECT and SPECT experiments were carried out as described (25) .
[123I]IBZM with specific activity >5000 Ci/mmol and radio- 10, 20 , and 40 min post-amphetamine injection. Because no statistically significant differences were observed between these three amphetamine measurements (repeated measures ANOVA, P = 0.17), the average values were used in subsequent analyses.
The clinical response to the amphetamine challenge was evaluated with the Positive and Negative Symptom Scales (29) . Baseline ratings were obtained 60 min before the first scanning session. Post-amphetamine ratings were obtained 30 min after the injection of amphetamine (i.e., during the interval between the first and second scanning session). For positive and negative subscales, a change of at least four points relative to baseline was considered clinically significant. Behavioral response was also rated by the subjects using a simplified version of the Amphetamine Interview Rating Scale (30) . Self ratings for euphoria, restlessness, alertness, and anxiety were obtained at various intervals, using a ten-point analog scale (25) . Responses were calculated as peak minus baseline scores.
SPECT data were analyzed blind to the diagnosis. Count projections were prefiltered using a Wiener 0.5 filter and backprojected using a ramp filter. SPECT images were reoriented to the cantho-meatal line as visualized by four external fiducial markers glued to the subject's head. The four slices with highest striatal uptake were summed and attenuation corrected assuming uniform attenuation. Standard region of interest profiles (striatum 556-mm2; occipital 2204 mm2) were positioned on the summed images. The camera resolution did not allow differentiating counts originating from the dorsal (sensorimotor) or ventral (limbic) striatum. Thus, the striatal region included both components. Right and left striatal regions were averaged. Striatal specific binding was calculated as striatal minus occipital activity. The occipital region was selected as the background region because (i) the density of dopamine D2 receptors is negligible in this region compared with the striatum (31); (ii) this region can be identified with greater reliability than the cerebellum; and (iii) in humans,
[123I]IBZM activity in the occipital region is equal to the nonspecific activity in the striatum (32 (1996) ~~Proc. Nati. Acad. Sci. USA 93 (1996) 9237 per ml of plasma) measured during scanning session 1 (25 35 ± 9(12) Values are mean ± SEM. Number of subjects (n) are in parentheses. *Unpaired two-tailed t test; P = 0.014.
we also performed nonparametric analyses on this variable with similar results (unpaired analysis: Mann-Whitney U, P = 0.034; paired analysis: Wilcoxon Signed Rank, P = 0.014).
No significant between-groups difference was observed in amphetamine plasma levels (P = 0.41; Table 2 ). No correlation was observed between amphetamine plasma levels and amphetamine-induced decreases in [1231]IBZM binding potential, either in the entire sample (r = 0.08, P = 0.68) or in each group considered separately (schizophrenics, r = 0.24, P = 0.45; controls, r = 0.14, P = 0.63). Consequently, the group difference in amphetamine-induced [1231]IBZM binding potential decrease could not be attributed to differences in amphetamine disposition. Amphetamine induced a transient (60-90 min) increase in systolic and diastolic blood pressure. The blood pressure response did not differ between the groups (peak systolic blood pressure above baseline: schizophrenics, 43 ± 5 mm Hg; controls, 49 ± 4 mm Hg, P = 0.31; peak diastolic above baseline: schizophrenics, 18 + 2 mm Hg; controls, 22 ± 2 mm Hg, P = 0.11).
No psychotic symptoms were observed after the amphetamine injection in controls. In patients, the clinical response was heterogeneous. Amphetamine induced clinically significant worsening in positive psychotic symptoms in six patients, improvement in three patients, and no significant change in six patients. This distribution was consistent with the previously reported prevalence of psychotic reactions to acute challenge with dopamine agonists in schizophrenia (26) . Negative symptoms improved significantly in four patients and did not change in 11 patients. All observable clinical changes were transient and, by the end of the experiment, patients had recovered their pre-amphetamine clinical status.
Schizophrenic patients who experienced worsening in positive symptoms showed larger reductions in [1231]IBZM binding potential (-27.6 ± 6.4%, n = 6) than schizophrenic patients whose positive symptoms did not worsen (-14.1 + 4.6%, n = 9) and healthy controls (-7.6 + 2.1%, n = 15, ANOVA: F = 6.31, P = 0.0056, Kruskal-Wallis: P = 0.031). In the schizophrenic group, the magnitude of the amphetamine effect on [1231]IBZM binding potential was positively correlated with changes in positive symptoms (r = 0.53, P = 0.038; Fig. 3 ). Such a correlation was not observed with changes in negative symptoms (r = 0.40, P = 0.14). Schizophrenic and controls did not differ in general behavioral activation scores measured with the Amphetamine Interview Rating Scale: euphoria (schizophrenics, +2.0 + 0.5; controls, +2.7 ± 0.5,P = 0.35), restlessness (schizophrenics, +2.6 + 0.6; controls, +1.8 ± 0.5, P = 0.34), alertness (schizophrenics, +2.5 ± 0.4; controls, +2.5 + 0.7, P = 1), and anxiety (schizophrenics, +2.7 + 0.5; controls, +2.6 + 0.6, P = 0.87).
In the schizophrenic group, the amphetamine effect on (8, 10) . Therefore, while a contribution of the affinity factor cannot be definitively excluded, an increased concentration of dopamine in the vicinity of the receptors is likely to be the predominant mechanism underlying the observed effect.
Amphetamine increases extracellular dopamine concentration by various mechanisms: facilitation of transportermediated release of cytoplasmic dopamine (38) , redistribution of dopamine from vesicular to cytoplasmic pool (39), inhibition of uptake (40) , inhibition of monoamine oxidase activity (41) , and calcium-dependent stimulation of dopamine synthesis (42) . Any of these factors could be implicated in the exaggerated response observed in the patients. Interestingly, a recent positron emission tomography study has reported increased accumulation of the dopamine precursor 6-[18F]fluoro-L-dopa in the striatum of patients with schizophrenia (43) . An increase in enzymatic activity associated with dopamine synthesis might lead to the constitution of larger cytoplasmic and/or vesicular pool and to a larger amphetamine-induced dopamine release.
The mechanism of this putative increased dopaminergic neuronal reactivity remains to be elucidated. Corticofugal glutamatergic projections that increase the responsiveness of dopaminergic subcortical systems are inhibited by dopaminergic prefrontal projections, both directly and indirectly via GABAergic interneurons (44, 45) . This glutamatergic cortical control occurs primarily through projections to the dopamine cell body area rather than the terminal region (46) . In nonhuman primates, selective destruction of dopamine terminals in dorsolateral, medial, and orbital regions of the prefrontal cortex does not affect striatal baseline dopamine concentration but induces a long-lasting increase in striatal potassiuminduced dopamine release (47) . Since potassium, like amphetamine, stimulates both dopamine synthesis and release (48) , this observation is potentially relevant to the present finding. Thus, the increased responsiveness of subcortical dopamine neurons observed in this study might be secondary to prefrontal dopaminergic or GABAergic deficits as both deficits have been proposed as constituents of the "cortical pathology" in schizophrenia (49, 50) .
A large variability in the amphetamine effect was evident in the schizophrenic group, and three patients showed lower amphetamine-induced [123I]IBZM displacement than their matched controls. This heterogeneity in the biochemical response to amphetamine matched the heterogeneity of the clinical response well and indicated that the abnormality revealed by this study is not present in all patients with schizophrenia. The 
